Results 31 to 40 of about 218,870 (301)

Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency.

open access: yesPLoS ONE, 2019
Doxorubicin is a chemotherapeutic agent that is commonly used to treat a broad range of cancers. However, significant cardiotoxicity, associated with prolonged exposure to doxorubicin, limits its continued therapeutic use.
Christina Schindler   +7 more
doaj   +1 more source

TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC

open access: yesTumor Biology, 2017
The anticancer effect of doxorubicin is closely related to the generation of reactive oxygen species. On the contrary, doxorubicin-induced reactive oxygen species induces heart failure, a critical side effect of doxorubicin.
Yun Sun Lee   +5 more
doaj   +1 more source

Platelet-rich plasma inhibits Adriamycin-induced inflammation via blocking the NF-κB pathway in articular chondrocytes

open access: yesMolecular Medicine, 2021
Background Previous studies showed that doxorubicin could lead to osteoarthritis (OA) by inducing chondrocyte inflammation and apoptosis. Besides, it is reported that platelet-rich plasma (PRP) could suppress the activation of inflammatory NF-κB ...
Haijun Zhao   +3 more
doaj   +1 more source

Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization

open access: yesBMC Cancer, 2012
Background Since proteins involved in chemotherapy drug pharmacokinetics and pharmacodynamics have a strong impact on the uptake, metabolism, and efflux of such drugs, they likely play critical roles in resistance to chemotherapy drugs in cancer patients.
Heibein Allan D   +4 more
doaj   +1 more source

Electrochemical Behaviour of Doxorubicin Encapsulated in Apoferritin

open access: yesInternational Journal of Electrochemical Science, 2013
A voltammetric detection of doxorubicin and encapsulated doxorubicin in apoferritin structure at a carbon paste electrode is the main aim of this study. The samples were measured by differential pulse voltammetry in phosphate buffer (pH 5.5).
Katerina Tmejova   +11 more
doaj   +1 more source

Efficient chemotherapy of rat glioblastoma using Doxorubicin-loaded PLGA nanoparticles with different stabilizers

open access: yes, 2011
Background: Chemotherapy of glioblastoma is largely ineffective as the blood-brain barrier (BBB) prevents entry of most anticancer agents into the brain.
Markus Glatzel   +14 more
core   +1 more source

Potential Roles of Melatonin in Doxorubicin-Induced Cardiotoxicity: From Cellular Mechanisms to Clinical Application

open access: yesPharmaceutics, 2023
Doxorubicin is a potent chemotherapeutic drug; however, its clinical application has been limited due to its cardiotoxicity. One of the major mechanisms of doxorubicin-induced cardiotoxicity is the induction of oxidative stress.
Tanawat Attachaipanich   +2 more
doaj   +1 more source

Temozolomid und pegyliertes liposomales Doxorubicin in Kombination mit Strahlentherapie in der Ersttherapie von Patienten mit Glioblastom WHO Grad IV – eine Phase I/II – Studie (RNOP – 09)

open access: yes, 2011
Hintergrund: Die EORTC26981/NCIC-CE.3-Studie hatte 2005 zur Etablierung eines neuen Standard-Therapieregimes für das Glioblastom geführt. Obwohl sich Temozolomid hierbei als wirksames Agens gezeigt hatte, bleibt die Prognose für diese Entität sehr ...
Schmid, Christina
core   +1 more source

Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse. [PDF]

open access: yesPLoS ONE, 2013
The antineoplastic efficacy of anthracyclines is limited by their cardiac toxicity. In this study, we evaluated the toxicity of doxorubicin, non-pegylated liposomal-delivered doxorubicin, and epirubicin in HL-1 adult cardiomyocytes in culture as well as ...
Stefano Toldo   +12 more
doaj   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy